WIKIMEDIA, NIAMSThermo Fisher Scientific said Friday (January 8) that it would acquire Affymetrix for $1.3 billion. According to MarketWatch, the boards of both companies have agreed to the deal, which must still be approved by Affymetrix shareholders.

“The acquisition of Affymetrix will strengthen our leadership in biosciences and create new market opportunities for us in genetic analysis,” Thermo Fisher President and CEO Marc Casper said in a statement (via 24/7 Wall Street). Frank Witney, president and CEO of Affymetrix, added: “We will be able to build on our strong history of close collaboration with customers in our target markets by leveraging Thermo Fisher’s deep relationships, particularly in biopharma.”.

(Hat tip: The Wall Street Journal)

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Join for free todayAlready a member?Login Here